Despite artificial intelligence’s growing role in drug research, a fully AI-generated molecule has yet to advance from discovery all the way through clinical development. A novel molecule may eventually meet that goal, but some industry observers say it’s too early to focus on winning a race that has many twists and turns yet to come.
The integration of AI into cardiology workflows can help triage care automatically, ensuring the right physicians weigh in on patient data at the right time which may potentially improve clinical outcomes for all patients in need.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Through rigorous validation processes, unwavering transparency, gradual implementation, and a steadfast commitment to preserving the human touch, healthcare IT providers can unequivocally demonstrate that AI is a reliable and trustworthy ally in the intricate and evolving landscape of healthcare.
I work as a cardiologist for a multi-specialty group that sees patients both in capitated payer and fee-for-service environments. This diverse practice gives me the experience to know where insurance providers will find value or what they will likely pay for. As these protocols become more scientifically validated, AI is going to help the entire healthcare system to identify at-risk patients quickly and accurately.
To digitize healthcare and lean on the emerging technologies is to find the opportunity within the relationship between machine and human to augment humans’ ability to be human – to empathize and provide the compassionate touch to care.
Putting all the AI pieces into place effectively requires clarity of what organizations want to accomplish - and for much of healthcare, the Quadruple Aim remains at the very top. Although how to get there will look different, clarity on principles and values that will guide the development of what comes next is paramount to setting us up for years to come.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
AI technologies have a role in the life sciences that goes beyond drug discovery. A panel at the MedCity News INVEST conference in Dallas discussed how new tech platforms help speed up the process of recruiting patients and running clinical trials.
At HLTH, Shaun Miller — Cedars-Sinai's chief medical information officer — pointed out one thing he thinks healthcare AI companies haven’t quite gotten right yet. He said he would “really like there to be a lot more recognition around the personalization of AI and the ability for technology to understand that not every clinician is the same.”
In a preview before the official announcement at HLTH last week, Microsoft executives and its hospital customers shared use cases of how its suite of AI tools can be used by health systems to improve healthcare delivery and alleviate provider burnout.
The FDA's digital health advisory committee will discuss technologies such as artificial intelligence and machine learning, virtual reality, and digital therapeutics as well as topics like decentralized clinical trials and patient-generated health data. Committee member nominations are due in December.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Formed by Baidu founder and CEO Robin Li, BioMap uses artificial intelligence technology to glean insight into proteins to guide biologic drug discovery. The startup is the latest company to join a growing list of Sanofi partners as the pharmaceutical giant continues investing in AI-enabled drug discovery.
Iambic Therapeutics brings together software engineers and drug-hunting scientists, all sharing the goal of using artificial intelligence to optimize properties of small molecule drugs. The startup will apply its Series B financing to a cancer drug pipeline that includes two candidates on track for the clinic in 2024.
It’s critical that we address these examples of institutionalized bias and racism in how we approach clinical trials for drugs and devices. While it’s a daunting task, the path forward is surprisingly clear, and AI can be instrumental in the next step of overcoming unconscious biases inherent in clinical trial processes.
Novo Nordisk is paying Valo Health $60 million up front to gain three preclinical cardiovascular disease programs. Milestone payments for those programs and others covered under the artificial intelligence drug discovery pact could reach up to $2.7 billion.
Specific targets were not disclosed, but Merck KGaA is betting the artificial intelligence technologies of Exscientia and BenevolentAI will discover new drugs for cancer, neurology, and immunology.